Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serological and molecular diagnosis.

Scott Bowden1

  • 1Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia.

Seminars in Liver Disease
|May 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

Liver international : official journal of the International Association for the Study of the Liver·2024
Same author

Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.

The Journal of infectious diseases·2022
Same author

Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?

Journal of acquired immune deficiency syndromes (1999)·2020
Same author

HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.

Journal of viral hepatitis·2020
Same author

Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.

Liver international : official journal of the International Association for the Study of the Liver·2019

Hepatitis B virus (HBV) DNA testing offers a clearer diagnosis than serological assays alone. HBV DNA quantification aids in monitoring antiviral treatment effectiveness and detecting drug resistance.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Diagnostics

Background:

  • Serological assays for hepatitis B surface antigen (HBsAg) are crucial for diagnosing hepatitis B virus (HBV) infection.
  • These assays help determine acute or chronic infection, past exposure, or vaccination status.
  • However, atypical or ambiguous serological profiles can complicate diagnosis.

Purpose of the Study:

  • To explore the utility of HBV DNA testing in clarifying hepatitis B diagnosis.
  • To highlight the role of HBV DNA quantification in monitoring antiviral therapy.
  • To assess the application of molecular diagnostics in HBV-infected liver tissue.

Main Methods:

  • Utilizing HBV DNA testing to resolve diagnostic ambiguities from serological assays.
  • Quantifying HBV DNA levels to monitor antiviral treatment efficacy.

Related Experiment Videos

  • Applying molecular techniques to analyze intrahepatic HBV DNA.

    • Main Results:

    • HBV DNA testing can elucidate an individual's true hepatitis B status when serology is unclear.
    • Quantification of HBV DNA is effective for monitoring antiviral therapy.
    • Molecular diagnostics in liver tissue show potential for monitoring and predicting treatment efficacy.

    Conclusions:

    • HBV DNA testing provides a valuable adjunct to serological assays for accurate hepatitis B diagnosis.
    • Quantification of HBV DNA is essential for effective management of antiviral therapy and resistance monitoring.
    • Further validation of molecular techniques for intrahepatic HBV DNA is needed for routine clinical use.